TSE:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis C$1.51 0.00 (0.00%) As of 03:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Cardiol Therapeutics Stock (TSE:CRDL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's RangeC$1.47▼C$1.5450-Day RangeC$1.51▼C$2.2352-Week RangeC$1.23▼C$2.33Volume57,673 shsAverage Volume104,748 shsMarket CapitalizationC$174.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). Read More Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRDL Stock News HeadlinesCardiol Therapeutics (TSE:CRDL) Trading Down 4.9% - Here's What HappenedJune 4, 2026 | americanbankingnews.comHere's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn SituationMay 15, 2026 | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.June 9 at 1:00 AM | Banyan Hill Publishing (Ad)Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash PositionMay 13, 2026 | theglobeandmail.comAnalysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before LongJanuary 12, 2026 | finance.yahoo.comHC Wainwright & Co. Reiterates Cardiol Therapeutics (CRDL) Buy RecommendationDecember 2, 2025 | msn.comCardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx™December 1, 2025 | msn.comCardiol Therapeutics Reports Q3 2025 Financial Results Amidst Cash DecreaseNovember 13, 2025 | msn.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at C$1.31 on January 1st, 2026. Since then, CRDL stock has increased by 13.7% and is now trading at C$1.49. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (TSE:CRDL) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.10) earnings per share for the quarter. How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include Cardiol Therapeutics (CRTPF), Rolls-Royce Holdings plc (RR.L), Very Good Food (VRYYF), Gilead Sciences (GILD), Luminar Technologies (LAZR) and Meta Platforms (META). Company Calendar Last Earnings5/11/2026Today6/09/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolTSE:CRDL CIKN/A Webwww.cardiolrx.com Phone289 910 0850FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$42.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-229.16% Return on Assets-54.15% Debt Debt-to-Equity Ratio0.48 Current Ratio4.39 Quick Ratio6.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$1.54 per share Price / Cash Flow0.98 Book ValueC$0.22 per share Price / Book6.80Miscellaneous Outstanding Shares115,272,000Free FloatN/AMarket CapC$174.06 million OptionableNot Optionable Beta0.37 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (TSE:CRDL) was last updated on 6/9/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
